Adaptable tissue-specific endothelial cells for organ regeneration

用于器官再生的适应性组织特异性内皮细胞

基本信息

  • 批准号:
    10594461
  • 负责人:
  • 金额:
    $ 101.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-01 至 2027-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT ABSTRACT The overarching goal of our proposed research program is to develop a discovery pipeline that will enable identification of transcriptional codes for engineering tissue-specific endothelial cells (ECs) for therapeutic organ regeneration of heart, lung and blood. Therapies for organ regeneration promises unlimited access to the replacement tissues. However, despite breakthroughs in uncovering the molecular underpinnings of organ morphogenesis and organoid technology, translation of regenerative medicine to the clinic has confronted with hurdles. These bottlenecks are in part due to the lack of understanding as to how niche cells coordinate organ repair. Specifically, contribution of vascular niche cells that supply regenerative signals has not been realized. This R35 application builds upon the novel proposition that poor healing after organ damage is due to the dysfunction and loss of the tissue-specific ECs. This programmatic proposal examines the hypothesis that reconstitution of stem cells in injured organs is dependent on the pro-regenerative angiocrine signals supplied by tissue-specific vascular niche ECs. We have shown that organotypic ECs by deploying defined angiocrine factors support lung, cardiac, hepatic and hematopoietic regeneration. Thus, ECs perform actively as dynamic, tissue-specified niche cells critical for tissue homeostasis and repair. To test this and to set up the stage for therapies, we have engineered adaptable mouse, nonhuman primate and human ECs by transducing the transduction factor (TF) ETV2 into adult mature ECs (R-VECs) and differentiating human induced pluripotent stem cells (iPSCs) into generic fetal-like ECs (iVECs) that could inform on the pathways that induce organotypic TFs. These adaptive iVECs and R-VECs will be cocultured with heart, lung, and blood organoids in vitro or infused in vivo in mice undergoing organ repair to identify the induction of organotypic TFs in these cells. The educated iVECs and R-VECs will be recovered and subjected to RNA profiling and de novo motif discovery to identify induced tissue-specific TF(s). The identified TFs will be overexpressed or knocked down in ECs, to validate their function in sustaining organotypic and angiocrine profile for organ repair. We anticipate that transplantation of organotypic ECs will promote long-lasting tissue repair without provoking tumorigenesis or fibrosis. We have initiated FDA-approved human clinical trials to examine the safety and efficacy of allogeneic generic EC infusion for hematopoietic recovery. As a follow up, we intend to assess the contribution of R-VECs or iVECs-derived from nonhuman primates to regeneration in the pigtail macaque monkeys with the intention of translating the potential of organotypic ECs to clinic. The expected outcomes of the proposed research are identification of molecular signals and transcriptional determinants of tissue-specific vascular and angiocrine heterogeneity. Goals of this proposal fit with the mission of NHLBI R35 award to develop innovative regenerative discovery pipeline to promote safe and efficacious treatments for cardiac, pulmonary and blood maladies.
项目摘要 我们提出的研究计划的总体目标是开发一个发现管道, 鉴定用于治疗的工程化组织特异性内皮细胞(EC)的转录代码 心脏、肺和血液的器官再生。器官再生疗法承诺无限制地获得 替换组织然而,尽管在揭示器官的分子基础方面取得了突破, 形态发生和类器官技术,将再生医学转化为临床所面临的问题 障碍。这些瓶颈部分是由于缺乏对小生境细胞如何协调器官功能的理解。 修复.具体而言,供应再生信号的血管小生境细胞的贡献尚未被认识到。 该R35应用建立在器官损伤后愈合不良是由于 组织特异性EC的功能障碍和丧失。本方案提案审查了以下假设: 损伤器官中干细胞的重建依赖于所提供的促再生血管分泌信号 通过组织特异性血管生态位EC。我们已经证明,通过部署确定的血管分泌,器官型EC 因子支持肺、心脏、肝和造血再生。因此,EC作为动态的, 组织特异性小生境细胞对组织稳态和修复至关重要。为了测试这一点, 我们已经通过转导细胞因子基因工程改造了适应性强的小鼠、非人灵长类动物和人类EC。 将转导因子(TF)ETV 2转化成成体成熟EC(R-VEC)和分化人诱导多能 将干细胞(iPSC)转化为通用的胎儿样EC(iVEC),可以告知诱导 器官型转录因子这些适应性iVEC和R-VEC将与心脏、肺和血液类器官共培养 在进行器官修复的小鼠中进行体外或体内输注,以鉴定这些小鼠中器官型TF的诱导。 细胞将回收受教育的iVEC和R-VEC,并进行RNA分析和从头基序 发现以鉴定诱导的组织特异性TF。识别的TF将被过度表达或敲除 在EC中,以验证它们在维持器官型和血管分泌特征以用于器官修复中的功能。我们预计 器官型内皮细胞的移植将促进持久的组织修复而不会引起肿瘤发生 或纤维化。我们已经启动了FDA批准的人体临床试验,以检查 同种异体通用EC输注用于造血恢复。作为后续行动,我们打算评估 的R-VEC或iVEC-来源于非人灵长类动物的猪尾猕猴再生, 目的是将器官型EC的潜力转化为临床。拟议工作组的预期成果 研究是鉴定组织特异性血管和 血管分泌异质性。该提案的目标符合NHLBI R35奖的使命,即开发创新的 再生发现管道,以促进心脏,肺和血液的安全有效治疗 疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shahin Rafii其他文献

Blood flow forces liver growth
血流推动肝脏生长
  • DOI:
    10.1038/d41586-018-06741-2
  • 发表时间:
    2018-09-26
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Sina Y. Rabbany;Shahin Rafii
  • 通讯作者:
    Shahin Rafii

Shahin Rafii的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shahin Rafii', 18)}}的其他基金

Molecular Determinants of liver sinusoidal endothelial cells for hepatic regeneration
肝窦内皮细胞肝再生的分子决定因素
  • 批准号:
    10682071
  • 财政年份:
    2023
  • 资助金额:
    $ 101.78万
  • 项目类别:
Adaptable tissue-specific endothelial cells for organ regeneration
用于器官再生的适应性组织特异性内皮细胞
  • 批准号:
    9894491
  • 财政年份:
    2020
  • 资助金额:
    $ 101.78万
  • 项目类别:
Adaptable tissue-specific endothelial cells for organ regeneration
用于器官再生的适应性组织特异性内皮细胞
  • 批准号:
    10397474
  • 财政年份:
    2020
  • 资助金额:
    $ 101.78万
  • 项目类别:
Deciphering molecular determinants of vascular heterogeneity for organ repair
破译器官修复血管异质性的分子决定因素
  • 批准号:
    9115995
  • 财政年份:
    2014
  • 资助金额:
    $ 101.78万
  • 项目类别:
Deciphering molecular determinants of vascular heterogeneity for organ repair
破译器官修复血管异质性的分子决定因素
  • 批准号:
    9327054
  • 财政年份:
    2014
  • 资助金额:
    $ 101.78万
  • 项目类别:
Deciphering molecular determinants of vascular heterogeneity for organ repair
破译器官修复血管异质性的分子决定因素
  • 批准号:
    8932020
  • 财政年份:
    2014
  • 资助金额:
    $ 101.78万
  • 项目类别:
Identification of vascular-derived signals for alveolar lung repair
识别肺泡肺修复的血管源信号
  • 批准号:
    8708964
  • 财政年份:
    2013
  • 资助金额:
    $ 101.78万
  • 项目类别:
Identification of vascular-derived signals for alveolar lung repair
识别肺泡肺修复的血管源信号
  • 批准号:
    8563169
  • 财政年份:
    2013
  • 资助金额:
    $ 101.78万
  • 项目类别:
Identification of vascular-derived signals for alveolar lung repair
识别肺泡肺修复的血管源信号
  • 批准号:
    8856658
  • 财政年份:
    2013
  • 资助金额:
    $ 101.78万
  • 项目类别:
Identification of vascular inductive signals in liver regeneration
肝再生中血管诱导信号的识别
  • 批准号:
    8444425
  • 财政年份:
    2012
  • 资助金额:
    $ 101.78万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 101.78万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 101.78万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 101.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 101.78万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 101.78万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 101.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 101.78万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 101.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 101.78万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 101.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了